Inhibitors of mutant idh1 and idh2

A compound of Formula I or Formula II

• or a pharmaceutically acceptable salt thereof, wherein
• L is chosen from C1-6 alkylene, C3-7 cycloalkylene, 3- to 7-membered heterocycloalkylene, arylene, and heteroarylene, any of which may be optionally substituted with one or more R3;
• Q is chosen from —O—, —CRcRd—, and ═CRc—;
• X is chosen from CH, CF, and N;
• Y is absent or is chosen from arylene and heteroarylene, either of which may be optionally substituted with one or more R3;
• Z is a saturated or partially unsaturated bivalent C4-10 hydrocarbon chain optionally substituted with one or more Ra, wherein 1 or 2 nonconsecutive methylene units of the chain may be independently replaced by —O—, —OC(O)—, —C(O)O—, —C(O)—, —NRbC(O)—, —C(O)NRb—, —OC(O)NRb—, or —NRbC(O)O—;
• each Ra is independently chosen from C1-6 alkyl, C3-8 cycloalkyl, halo, C1-6 haloalkyl, C1-6 alkoxy, aryl, and heteroaryl;
• each Rb is independently chosen from hydrogen and C1-6 alkyl;
• Rc is chosen from hydrogen, C1-6 alkyl, C3-8 cycloalkyl, halo, C1-6 haloalkyl, C1-6 alkoxy, aryl, and heteroaryl;
• Rd is chosen from hydrogen and C1-6 alkyl;
• R1 is chosen from hydrogen, halo, hydroxyl, and amino;
• R2a and R2b are independently chosen from hydrogen, methyl, and halomethyl;
• and
• each R3 is independently chosen from C1-6 alkyl, C3-7 cycloalkyl, C1-6haloalkyl, 3- to 7-membered heterocycloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, cyano, halo, and hydroxy.